Vitiligo on the Back: Treatment Guide
Back vitiligo responds reasonably well to treatment but comes with a practical application problem: you can't easily reach it yourself. Here's how to actually manage that.
Category
Vitiligo Treatments
103 articles — page 2 of 9
Vitiligo on Knees and Elbows: Treatment Guide
Knees and elbows are bony, low-follicle-density areas that respond more slowly than most body sites — but they're not untreatable. Here's what to expect.
Vitiligo on the Neck and Chest: Treatment Guide
The neck and chest respond reasonably well to treatment but bring their own sun exposure and clothing-friction considerations. Here's what to know.
Zinc vs. Vitamin D for Vitiligo: Which Actually Matters More
Both come up constantly in vitiligo supplement discussions. Here's how their evidence actually compares, and which one is more likely to be worth your money.
Eyebrow Microblading for Vitiligo: Restoring Lost Brow Pigment
When vitiligo affects eyebrow hair or the skin beneath it, microblading is a specific semi-permanent option worth understanding on its own terms.
Micropigmentation for Vitiligo: Paramedical Tattooing for Stable Patches
For stable, treatment-resistant patches, medical micropigmentation deposits pigment into the skin as a semi-permanent camouflage option. Here's how it differs from decorative tattooing and what it actually involves.
Repigmentation Timeline by Treatment Type: What to Realistically Expect
Every vitiligo treatment has a different realistic timeline before you can fairly judge whether it's working. Here's a side-by-side comparison so you know what to expect from each one.
Should I Stop Opzelura If I'm Not Seeing Progress?
The timeline for judging whether Opzelura is working is longer than most people expect, and stopping too early is one of the most common reasons it gets written off unfairly. Here's a realistic framework.
Povorcitinib for Vitiligo: The Newest Oral Pill in the Pipeline
Incyte's povorcitinib met its Phase 3 endpoints in May 2026 — another oral JAK1/TYK2 inhibitor joining upadacitinib and ritlecitinib in the race for systemic vitiligo treatment. Here is what it is and what it means for patients now.
TEV-53408: The Anti-IL-15 Antibody That Could Mean Durable Vitiligo Remission
Teva paid Royalty Pharma $500 million for TEV-53408, an anti-IL-15 antibody now in Phase 1b trials for vitiligo. Unlike JAK inhibitors, it targets the memory T cells responsible for relapse — meaning it may allow remission to last after treatment stops.
Vitiligo and Stress Reduction: What Meditation and Mindfulness Can Actually Do
Stress is often linked to vitiligo flares. But what does the research actually say about meditation and stress reduction as part of vitiligo management? An honest look at the evidence.
World Vitiligo Day 2026: The Treatment Advances That Actually Matter
World Vitiligo Day 2026 falls at a genuinely significant moment for treatment. An oral JAK inhibitor is awaiting FDA approval, a second has Phase 3 wins, NHS patients can now access Opzelura, and a new Phase 3 study confirmed baricitinib efficacy. Here is what is real and what it means.
